Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial

Abstract

Addition of the AKT inhibitor capivasertib to first-line paclitaxel therapy for TNBC resulted in significantly longer PFS and OS. Benefits were more pronounced in patients with <i>PIK3CA</i>/<i>AKT1</i>/<i>PTEN</i>-altered tumors. Capivasertib warrants further investigation for treatment of TNBC.